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Abstract We examined the diversity of single receptor function
by measuring receptor^G protein coupling in the baculovirus^
Sf21 expression system. In comparative studies using Sf21 cell
membranes expressing U-opioid receptor (KOR) plus GKi1L1Q2 or
KOR plus GKoAL1Q2, there was no significant difference between
both preparations in the Ki values of various U-opioid ligands for
the displacement of [3H]U69593 binding. However, a marked
difference in the rank order of agonists to stimulate [35S]GTPQS
binding was observed between both preparations. These findings
suggest that agonist efficacy is dependent on the population of
different G proteins expressed in various tissues.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
From recent advances in G protein-coupled receptor
(GPCR) studies, more complex coupling between GPCR
and G protein than previously expected in reconstitution ex-
periments using puri¢ed proteins [1,2] has been reported [3,4].
The facts adding the diversity in such functional couplings
may include the basal activity of GPCR without agonist stim-
ulation [3] and the existence of alternative splicing variants
showing di¡erent kinetics of internalization [4]. Opioid recep-
tors are the most representative GPCRs whose diverse func-
tions have been extensively characterized [2]. They were orig-
inally classi¢ed into W, N and U types, and they were all known
to be coupled with pertussis toxin-sensitive G protein, Gi or
Go [2,5], and these functional couplings have been con¢rmed
by reconstitution experiments using cloned receptors [6,7].
Although more than 20 opioid peptides including endorphins
have been discovered in mammals [8,9], only three opioid
receptor genes have been discovered even after extensive
searches [10]. From this reason it has been speculated that
each opioid receptor should have diverse sensitivities to di¡er-
ent opioid peptides in view of its functional e⁄cacy or kinetics
as well as binding a⁄nity. Although some diverse mechanisms
might be related to several alternatively splicing variants of
opioid receptors, it remains to be determined whether each
variant corresponds to each opioid peptide. Our strategy to
see this diverse functional sensitivity of opioid receptor to
agonists is the determination of agonist e⁄cacy in opioid re-
ceptor coupling to speci¢c G protein molecules. For this pur-
pose, analysis in reconstitution experiments using puri¢ed re-
combinant receptor and G protein seems to be ideal.
However, because of the instability of these proteins, we
have often met a big limitation in detailed analyses for func-
tional coupling. Recently a baculovirus expression system has
been introduced into the signal transduction study of recep-
tors. As abundant recombinant proteins are generally ex-
pressed, and multiple infections are easily performed in this
expression system, protein^protein interaction could be ana-
lyzed in detail using membrane preparations, under the mini-
mized consideration of naturally occurring proteins. Here we
report the diverse sensitivity of U-opioid receptor (KOR) to
various agonists under di¡erent quasi-reconstitution condi-
tions with di¡erent G proteins.
2. Materials and methods
2.1. Materials
(5a,7a,8b)-(+)-N-Methyl-N-(7-(pyrrolidinyl-1-oxaspiro-(4,5)dec-8-
(+)-yl) benzeneacetamide (U69593) was kindly provided by Upjohn
Japan, norbinaltorphimine (nor-BNI) by Dr. H. Nagase (Toray In-
dustries), rat KOR cDNA by Dr. K. Fukuda (Kyoto University).
[3H]U69593 (50.6 Ci/mmol) and [35S]GTPQS (1156 Ci/mmol) were
purchased from DuPont/NEN, EX-CELL 400 medium from JRH
Bioscience, TNM-FH medium from Sigma, wild-type baculovirus
(Autographa californica nuclear polyhedrosis virus, AcNPV) DNA
from Pharmingen, fetal bovine serum from PAA Laboratories, nitro-
cellulose transfer membrane from Schleicher and Schuell, and GF/B
glass ¢ber ¢lters from Whatman. All other chemicals were purchased
from Sigma.
2.2. Recombinant baculovirus of the U-opioid receptor
The cDNA of rat KOR was ampli¢ed using two synthetic oligo
primers complementary to the 5P and 3P ends of the coding region
and carrying a recognition site for XbaI on each end. The XbaI^XbaI
fragment of the PCR product was inserted into an NheI site down-
stream of the polyhedrin promoter in the transfer vector pJVP10Z
using cohesive end ligation [11]. The recombinant plasmid,
pJVP10Z/KOR, carrying the insert in the correct orientation was
identi¢ed by sequencing. The baculovirus transfer vector pJVP10Z
used in this study is based on pJV(NheI) [12] containing a L-galacto-
sidase gene, which allows blue/white screening via production of
L-galactosidase. The recombinant plasmid pJVP10Z/KOR was trans-
fected into Sf21 cells together with wild-type baculovirus (AcNPV)
DNA using a lipofectin-mediated co-transfection method [13]. A re-
combinant virus was plaque-puri¢ed by four rounds of color selection
using X-gal, and ampli¢ed four rounds.
2.3. Co-expression of the KOR and G proteins
Spodoptera frugiperda Sf21 cells were maintained in suspension cul-
ture in EX-CELL 400 medium containing 25 Wg/ml gentamicin at
27‡C, and for infection Sf21 cells were grown in TNM-FH medium
containing 10% fetal bovine serum and 25 Wg/ml gentamicin at 27‡C
[14]. Insect cells and baculovirus (AcNPV) were manipulated essen-
tially as described [15]. The Sf21 cells were seeded in 75 cm2 £asks
(Nunc) in TNM-FH insect medium (Sigma) containing 10% fetal bo-
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vine serum and infected with recombinant viruses at a multiplicity of
infection (m.o.i.) of 10 for KOR, 3 for GK subunit and 1 for GL1Q2
subunits [16] unless otherwise stated. GL1 and GQ2 subunits were
placed downstream of two polyhedrin promoters arranged back to
back in the recombinant virus coding both subunits. Cells were har-
vested 2^3 days after infection.
2.4. [35S]GTPQS binding assay
Cells were harvested, washed with phosphate-bu¡ered saline and
homogenized in 20 mM Tris^HCl bu¡er, pH 7.5 containing 1 mM
EDTA, 1 mM dithiothreitol with a Potter-type homogenizer. The
homogenate was centrifuged at 1000Ug for 10 min and the super-
natant was further centrifuged at 20 000Ug for 20 min. The resulting
pellet was resuspended in bu¡er A (20 mM HEPES, 1 mM MgCl2,
100 mM NaCl and 1 mM dithiothreitol, pH 7.5) to adjust at 0.3^1
mg/ml protein. In some studies MgCl2 was omitted to assess its role.
[35S]GTPQS binding assays were carried out as described [17]. The
membrane fractions from Sf21 cells were incubated with [35S]GTPQS
for 60 min or indicated periods at 30‡C.
2.5. [3H]U69593 binding
Membrane proteins (50^150 Wg) were mixed with 50 mM Tris^HCl
bu¡er, pH 7.5 with varying concentrations (0.5^5 nM) of the U-opioid
agonist [3H]U69593 in a total of 1 ml. The incubation was started by
addition of the membrane suspension and was carried out for 40 min
at 25‡C. The reaction was terminated by a rapid ¢ltration through
GF/B ¢lters presoaked in 0.1% polyethyleneimine, under vacuum. The
¢lters were washed six times with 3 ml of ice-cold 50 mM Tris^HCl
bu¡er, pH 7.5. Filters were transferred to scintillation vials containing
7 ml of Clearsol I scintillation cocktail (Nacalai Tesque) and bound
radioactivity was quantitated by liquid scintillation counting. In the
displacement experiments, 1 nM [3H]U69593 was used. In all experi-
ments, the non-speci¢c binding was represented as the binding activity
in the presence of 1 WM nor-BNI.
2.6. Immunoblot analysis
Membrane proteins (10 Wg), prepared from uninfected or infected
Sf21 cells, were heated in Laemmli sample bu¡er for 5 min at 95‡C
and subjected to SDS^polyacrylamide gel electrophoresis on a 4%
stacking/10% running gel [18]. SeeBlue Pre-Stained Standards (Novex)
were run in parallel. After electrophoresis, the resolved proteins were
electro-transferred to Immobilon transfer membranes (Millipore). The
membranes were sequentially incubated with antibodies recognizing
GKi1 (AS/7; rabbit antiserum, against C-terminal, 1:1000 dilution),
GK11 (rabbit antiserum, against C-terminal, 1:3000 dilution, [16]),
GKs (rabbit antiserum, against N-terminal, 1:3000 dilution), GKo
(rabbit antiserum, against N-terminal, 1:500 dilution), or GL1 (mouse
IgG, against N-terminal, 1:1500 dilution) for 3 h at room temper-
ature. Secondary incubations were performed for 2 h at room temper-
ature using goat anti-rabbit or anti-mouse IgG conjugated to horse-
radish peroxidase and bound enzyme was visualized with H2O2 and 4-
chloro-1-naphthol.
3. Results
3.1. Opioid agonist-stimulated [35S]GTPQS binding
Agonist stimulation of [35S]GTPQS binding is known to be
critical for the concentration of GDP to inhibit non-speci¢c
binding of [35S]GTPQS to the preparation. In preliminary
studies we observed that there was no signi¢cant stimulation
by U69593 in its absence or in the presence of a high concen-
tration (100 WM) of GDP in membrane preparations from
Sf21 cells infected with GKi1 and GL1Q2 viruses together
with KOR virus. At concentrations of GDP between 0.3
and 10 WM, however, basal levels were decreased, giving rise
to signi¢cant agonist-induced stimulation (Fig. 1A). When the
in£uence of Mg2 on the binding of [35S]GTPQS was inves-
tigated in the absence and presence of 1 WM U69593, the
condition in the presence of 1 mM Mg2 gave the best result
(Fig. 1B). Here we decided to use 3 WM GDP and 1 mM
Mg2 for standard assay conditions unless otherwise stated.
The U-opioid agonist U69593 stimulated the [35S]GTPQS bind-
ing in a concentration-dependent manner (Fig. 1C). The me-
dian e¡ective concentration (EC50) was 54.7 þ 11.1 nM (n = 3).
No signi¢cant stimulation of the binding was observed by
[D-Ala2,MePhe4,Gly5-ol]-enkephalin or [D-Ser2,Leu5]-enkeph-
alin-Thr6, speci¢c W- or N-opioid agonists [8], respectively
(data not shown). This stimulation by U69593 was completely
antagonized by the U-opioid antagonist nor-BNI (1 WM), in-
dicating the involvement of speci¢c U-opioid receptor in the
U69593-stimulated [35S]GTPQS binding.
3.2. Selective activation of Gi1 or GoA by KOR in the
reconstitution membrane
In membrane preparations of Sf21 cells infected with KOR
alone, 1 WM U69593 did not show any signi¢cant change in
the [35S]GTPQS binding for 3 h, as shown in Fig. 1D. When
Sf21 cells were infected with GL1Q2 and GKi1 or GKoA viruses
together with KOR virus, signi¢cant stimulation was observed
by 1 WM U69593 treatment (Fig. 1E,F). However, there was
no signi¢cant stimulation of [35S]GTPQS binding in prepara-
tions with GKs or GK11 virus (Fig. 1G,H), though protein
expression of four GK subunits and GL1 subunit was detected
in cell membranes by immunoblot analysis (Fig. 1I).
3.3. No change in the a⁄nities of various U-opioid ligands to
[3H]U69593 binding between preparations expressing
Gi1 or GoA
From Scatchard plot analysis, Kd and Bmax were calculated
to be 2.7 þ 0.5 nM and 139.5 þ 38.7 fmol/mg protein (n = 3) in
the preparation with KOR plus GKi1L1Q2, respectively, while
these values were 2.5 þ 0.5 nM and 97.4 þ 28.5 fmol/mg pro-
tein (n = 3) in the preparation with KOR plus GKoAL1Q2, re-
spectively. There was no signi¢cant di¡erence in Kd value
between both preparations, though some di¡erences in Bmax
were observed. The latter di¡erence may be attributed to dif-
ferent expression of either KOR or G protein. In the displace-
ment experiments the inhibitory e¡ects of various U-opioid
ligands on [3H]U69593 (1 nM) binding in both preparations
expressing Gi1 or GoA were examined. As shown in Fig. 2, all
these compounds markedly inhibited the binding in the range
of 1 nM to 1 WM in both preparations. However, there were
no signi¢cant di¡erences in the displacement curves by any
opioid ligands between the preparations. Detailed analysis
also con¢rmed this conclusion in view of Ki values (Table 1).
3.4. Di¡erent kinetic potencies of various U-opioid agonists in
di¡erent preparations expressing Gi1 or GoA
We characterized the kinetic potencies of U-opioid agonists
Table 1
Inhibition of speci¢c [3H]U69593 binding to membranes of KOR/




U69593 2.0 þ 0.3 2.2 þ 0.3
U50488H 1.8 þ 0.1 1.6 þ 0.3
DynA(1^17) 7.8 þ 3.6 4.3 þ 3.1
DynB 32.3 þ 14.5 25.9 þ 11.3
nor-BNI 13.6 þ 4.5 16.0 þ 5.6
Results represent the mean þ S.E.M. from three separate experiments
performed in duplicate.
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Fig. 1. Characterization of KOR-mediated [35S]GTPQS binding. In the experiments, monolayer cultures of Sf21 cells were infected with recombi-
nant viruses at a m.o.i. of 10 for KOR, 3 for GKi1 subunit and 1 for GL1Q2 subunits. Membrane fractions were prepared from the infected cells
after 72 h, and subjected to [35S]GTPQS binding assay. A, B: E¡ects of GDP (A) and Mg2 (B) on the binding of [35S]GTPQS to membranes
of Sf21 cells infected with KOR, GKi1 and GL1Q2 subunit viruses, and stimulation by 1 WM U69593. All results are from a single experiment
performed in duplicate. C: Antagonism of [35S]GTPQS binding stimulated by various concentrations of U69593 by nor-BNI (1 WM) in GKi1L1Q2
preparations. Results represent means þ S.E.M. from three separate experiments performed in duplicate. Basal [35S]GTPQS binding was
39.4 þ 6.3 pmol/mg of protein in the absence of U69593 (n = 3). D^H: U69593-induced stimulation of [35S]GTPQS binding to membranes of
Sf21 cells infected with KOR and GL1Q2 alone (D), plus GKi1 (E), GKoA (F), GKs (G) or GK11 viruses (H). Open and closed circles represent
the absence and presence of 1 WM U69593, respectively. I : Immunoblot analysis of GK subunits and GL subunit in Sf21 cells infected with
KOR and GL1Q2 with and without GKi1, GK11, GKs or GKo viruses.
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in the membrane from Sf21 cells expressing Gi1 or GoA. Be-
cause multiple-virus infection was needed to reconstitute the
expression system, the absolute value of [35S]GTPQS binding
was irregular in each experiment. To normalize the agonist
stimulation of the [35S]GTPQS binding from preparation to
preparation, each agonist-stimulated activity was evaluated
as percent of maximal stimulation caused by 100 WM
U69593. As shown in Fig. 3, no signi¢cant di¡erence in the
agonist stimulation of [35S]GTPQS binding between Gi1 and
GoA preparations was observed with U69593 and dynorphin
A (DynA) 1^17. However, there were signi¢cant di¡erences in
the pro¢les of agonist stimulation of [35S]GTPQS binding be-
tween both preparations with U50488H and DynB. The dif-
ference includes changes in the EC50 or maximal activity. In
the case of U50488H, the maximal stimulation of [35S]GTPQS
binding was lower in the preparation expressing Gi1 than in
the preparation expressing GoA. In the case of DynB, how-
ever, a higher sensitivity of agonist stimulation of [35S]GTPQS
binding was observed in the Gi1 preparation than in the GoA
preparation, where there was a marked parallel shift, but no
signi¢cant di¡erence in maximal e¡ects between preparations.
The EC20, EC50, and EC80 of GoA stimulation increased 10.0-,
50.3-, and 18.6-fold compared to those of Gi1 stimulation.
4. Discussion
Here we obtained two major ¢ndings in KOR^G protein
coupling. The ¢rst ¢nding is that KOR is coupled to Gi1 and
GoA in baculovirus-infected Sf21 cell membranes, which is
consistent with previous pharmacological reports which
showed the pertussis toxin-sensitive actions by U-opioid ago-
nists. In the present study, we con¢rmed that this receptor did
not couple with Gs or G11 which can be coupled with D1
dopamine receptor or lysophosphatidic acid receptor respec-
tively [19]. As the stoichiometry of receptor coupling to Gq=11
was reported to be very low, compared to Gi=o- or Gs-coupled
receptors [20], it is di⁄cult to prove this type of uncoupling
unless reconstitution with recombinant Gq=11 is performed.
Nakamura et al. [16] have reported that muscarinic M1 re-
ceptor stimulated the [35S]GTPQS binding to G11 in mem-
branes of Sf9 cells infected with M1 and G11 baculoviruses.
Most recently we have found that melittin, an amphiphilic
peptide, directly stimulated [35S]GTPQS binding in a prepara-
Fig. 2. Displacement of [3H]U69593 binding by various U-opioid ligands. Open and closed circles represent the results with GKi1L1Q2 and
GKoAL1Q2 preparations, respectively. Each data point represents the mean þ S.E.M. from three separate experiments.
Fig. 3. U-Opioid agonist-induced stimulation of [35S]GTPQS binding
in either GKi1L1Q2 (open circles) or GKoL1Q2 preparations (closed
circles). Each data point represents the mean þ S.E.M. from three
separate experiments. *P6 0.05, compared with the data with
GKoL1Q2 preparations at the same concentration of agonist (Stu-
dent’s t-test).
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tion from Sf21 cells infected with the G11 baculovirus, but not
in a preparation from uninfected cells [19]. Therefore, it is
evident that KOR is not functionally coupled to G11. Simi-
larly, as we have found that L2-adrenoceptors or D1 dopa-
mine receptors were coupled with Gs in in vivo reconstitution
experiments [17], the uncoupling between KOR and Gs is also
evident.
The second ¢nding is that the rank order of potencies of
various agonists in stimulation of [35S]GTPQS binding was
di¡erent between Gi1 and GoA preparations, while there was
no signi¢cant kinetic change in [3H]U69593 binding between
these preparations. In the displacement experiments of
[3H]U69593 binding, the inhibitory kinetics of various U-
opioid ligands were identical between preparations expressing
Gi1 and GoA.
On the other hand, all U-opioid agonists used here stimu-
lated [35S]GTPQS binding in both preparations expressing Gi1
or GoA. When the stimulated [35S]GTPQS binding by each
agonist was represented as percent of U69593 (100 WM)-
stimulated binding in either Gi1 or GoA preparations, di¡er-
ences in the sensitivity to each agonist between the two prep-
arations were observed (Fig. 3). Although there was no sig-
ni¢cant di¡erence between preparations in the case of U69593
and DynA(1^17), both U50488H and DynB showed signi¢-
cant di¡erences between preparations. Interestingly, the di¡er-
ence was observed in the kinetics. A marked decrease in the
maximum e¡ect was observed with U50488H-stimulated
[35S]GTPQS binding in GoA preparations, without a change
in ED50, compared to the Gi1 preparations. In contrast, a
lower sensitivity to DynB when evaluated by ED50 was ob-
served in Gi1 preparations than in GoA preparations, without
any change in the maximal e¡ect. Thus, all these ¢ndings
suggest that the rank order and kinetic e⁄cacy of agonists
in the stimulation of [35S]GTPQS binding di¡er in preparations
coexpressing di¡erent G proteins. Taking into account the
fact that Go is abundant in the brain, but not in the periphery
[21], compared with Gi1, the physiological signi¢cance of
DynB in the brain should be less than in the periphery.
In conclusion, here we demonstrated the di¡erent kinetic
e⁄cacy of opioid agonists in stimulating G protein in prepa-
rations expressing di¡erent G proteins. The present study may
provide a mechanism to answer the question how a single
opioid receptor distinguishes multiple opioid peptides.
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